Jiangsu Hengrui Pharmaceuticals (01276) receives the clinical trial approval notification for HRS-7535 tablets.

Jiangsu Hengrui Pharmaceuticals (01276) announced recently that its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. has received the approval notice for the drug clinical trial of HRS-7535 tablets issued by the National Medical Products Administration, and will soon start the clinical trial. HRS-7535 tablets are a new type of oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist. By activating human GLP-1R, it can promote insulin secretion from the pancreas and reduce glucagon secretion while inhibiting gastric emptying. It can also enhance satiety and suppress appetite through central effects, directly reducing energy intake. Preclinical data shows that HRS-7535 can significantly improve symptoms of chronic kidney disease (CKD) in animals. There is currently no oral small molecule GLP-1R agonist on the market worldwide. As of now, the cumulative research and development investment in the HRS-7535 project is approximately RMB 369.4 million (unaudited).